Relmada Therapeutics, Inc.
RLMD
$0.3621
-$0.0362-9.09%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -31.91% | 46.46% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -17.09% | 22.26% | |||
| Operating Income | 17.09% | -22.26% | |||
| Income Before Tax | 14.13% | -22.28% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 14.13% | -22.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 14.13% | -22.28% | |||
| EBIT | 17.09% | -22.26% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 14.13% | -22.26% | |||
| Normalized Basic EPS | 16.83% | -24.07% | |||
| EPS Diluted | 14.13% | -22.03% | |||
| Normalized Diluted EPS | 16.83% | -24.07% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||